BTIG analyst Ryan Zimmerman maintained a Buy rating on Zimmer Biomet Holdings (NYSE:ZBH) on Wednesday, setting a price target of $179, which is approximately 7.69% above the present share price of $166.22.
Zimmerman expects Zimmer Biomet Holdings to post earnings per share (EPS) of $0.95 for the second quarter of 2021.
The current consensus among 15 TipRanks analysts is for a Strong Buy rating of shares in Zimmer Biomet Holdings, with an average price target of $193.6.
The analysts price targets range from a high of $210 to a low of $160.
In its latest earnings report, released on 03/31/2021, the company reported a quarterly revenue of $1.85 billion and a net profit of $300.8 million. The company's market cap is $34.65 billion.
According to TipRanks.com, BTIG analyst Ryan Zimmerman is currently ranked with 5 stars on a 0-5 stars ranking scale, with an average return of 32.0% and a 59.61% success rate.
Zimmer Biomet Holdings, Inc. is a musculoskeletal healthcare company. The company engages in designing, manufacturing and marketing orthopedic reconstructive products; biologics, sports medicine, extremities and trauma products; spine, dental implants, bone healing, craniomaxillofacial and thoracic products; and related surgical products.